LETS ROCKEN ROLL ON HUMAN GENOME'S's BENLYSTA

It's been over fifty years since the US Food and Drug Administration [FDA] has approved a new drug to treat the illness lupus, which turns a victim's body against it self, but all that can change this week as an approval decision is expected by Thursday for Human Genome Sciences lupus drug, Benlysta.

I became interested in the Human Genome Sciences Investments, as time went on I was able to buy stock options in the company. They achieved the first product sales in 2009 by delivering 20,000 doses of raxibacumab to the U.S. They secured a new purchase order in July 2009 for 45,000 doses of raxibacumab to be delivered over a three-year period and them also
Have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline.
The reason this company interested me was because my Mom was diagnose in the 1980’s with rheumatoid arthritis and lupus, during the next thirty years I saw her suffer with the pain and illness of these two deceases.  She tried all the drugs as they became available and some would help for a while but then would stop working and she would need to try something else.  Between the side effects of the drugs and the decease process you really had to be careful when you were around her because her immune system was so compromised you didn't want to be sick as you would most likely give it to her. I thought maybe she could be helped down the road but it was not meant to be, The Lord needed her in heaven more. On March 11, 2010 my Mom died. And although she did not get to see or try this newest round of drugs coming out we can only hope that others who suffer from the same deceases.